Yuhan Corporation clinical trials

The registry lists 172 studies whose lead sponsor is Yuhan Corporation or one of 3 companies grouped under it. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 →

• A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard TherapyRecruitingNCT05276310Phase 1

  Sponsor listed in the registry: ImmuneOncia Therapeutics Inc.

• Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorRecruitingNCT05523947Phase 1/2
• A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination TherapyNot yet recruitingNCT07816198Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946RecruitingNCT06616766Phase 1/2
• A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236BNot yet recruitingNCT07730567Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy AdultsNot yet recruitingNCT07717775Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male VolunteersNot yet recruitingNCT07722871Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNot yet recruitingNCT07717749Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male VolunteersNot yet recruitingNCT07715305Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsRecruitingNCT06975410Phase 1/2
• A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy AdultsNot yet recruitingNCT07618845Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231CNot yet recruitingNCT07590167Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the KneeNot yet recruitingNCT07550231Phase 2

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232Not yet recruitingNCT07538466Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid TumorRecruitingNCT06365840Phase 2

  Sponsor listed in the registry: ImmuneOncia Therapeutics Inc.

• Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-AntihistaminesRecruitingNCT07415551Phase 2
• A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy AdultsNot yet recruitingNCT07521241Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNot yet recruitingNCT07476157Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male SubjectsRecruitingNCT07444385Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy AdultsNot yet recruitingNCT07385248Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'RecruitingNCT07385235Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CNot yet recruitingNCT07312773Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322Not yet recruitingNCT07312799Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117ANot yet recruitingNCT07152873Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• The Food Effect on PK Characteristics and Safety Profiles of PA-111Not yet recruitingNCT06976489Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111ARecruitingNCT06932705Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120ANot yet recruitingNCT06916130Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284RecruitingNCT06884098Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-218RecruitingNCT05400317Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227BRecruitingNCT06441630Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral NutritionRecruitingNCT06625957Phase 3
• Phase III Study to Evaluate the Efficacy and Safety of AD-209RecruitingNCT06348576Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and ASRecruitingNCT05835518
• Bioequivalence Study Between YHP2508C and YHR2603 in Healthy SubjectsCompletedNCT07584304Phase 1
• A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeActive, not recruitingNCT04414163Phase 2

  Sponsor listed in the registry: ImmuneOncia Therapeutics Inc.

• A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory LymphomasCompletedNCT04306224Phase 1

  Sponsor listed in the registry: ImmuneOncia Therapeutics Inc.

• A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282CompletedNCT06747936Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-224CompletedNCT06291207Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male ParticipantsActive, not recruitingNCT06517914Phase 1
• A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male VolunteersCompletedNCT07103278Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy VolunteersCompletedNCT07470125Phase 1
• A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult VolunteersCompletedNCT07495514Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3
• Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionActive, not recruitingNCT06041529Phase 4
• Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute BronchitisCompletedNCT07111468Phase 3
• Bioequivalence Study Between YHP2406 and YHR2501 in Healthy SubjectsCompletedNCT07265167Phase 1
• A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227BCompletedNCT06884085Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'CompletedNCT06902818Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282CompletedNCT06858865Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy SubjectsCompletedNCT06920719Phase 1